Bristol-Myers To Pay Nektar $1.85B In Cash, Stock As Part Of Collaboration Pact

Bristol-Myers Squibb and Nektar Therapeutics announced the companies have executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.